

Editorial Policy for *Biological Psychiatry* Family of Journals: Editor Handling, Conflicts, & Disclosures

The *Biological Psychiatry* family of journals recognizes the importance of considering potential editorial conflicts of interest when processing and evaluating manuscript submissions. We therefore provide this policy to the scientific community as a means of offering transparency to the editorial policies of the journal. Editors of the journals will provide public disclosures of their financial interests over the last two years, and will differentiate those relationships by yearly monetary values of less than or equal to \$10,000, and those greater than \$10,000. The single exception to the monetary designation is research study support in the form of drug *only* (no other financial or material support). When only the study drug is supplied for a project, this will be listed in the minor conflict category. Editors will recuse themselves from evaluating or handling a paper according to the following rules:

- 1) In the event of a major conflict of interest (greater than \$10,000), the editor having such conflict will not have any involvement in the editorial process, including but not limited to evaluating, reviewing, commenting on or otherwise participating in editorial decision-making, regarding any manuscript believed to be related to the source of the conflict in any way. By way of example, an editor will not involve him/herself with manuscripts where any of the authors are employed at the same institution as the editor, nor will an editor have any involvement in the editorial process regarding manuscripts investigating any drug manufactured by a company in which the editor has a major conflict (as listed and defined in this policy).
- 2) Also in relation to major conflicts (greater than \$10,000), in cases where an editor has consulted with a company on a particular drug, the editor will recuse him/herself from involvement in the editorial process with regard to the entire class of agents, regardless of the funding source of the manuscript.
- 3) For minor conflicts of interest (equal to or less than \$10,000) or those with drug support only, editors will recuse themselves from the editorial process in connection with manuscripts only in instances involving the specifics of their relationship (i.e., manuscripts that report on the specific drug with which the editor has a relationship).
- 4) Because not all potential conflicts of interest are financial in nature, editors shall recuse themselves from the editorial process regarding any manuscript in connection with which the editor believes he/she cannot provide an impartial, unbiased opinion. This includes, but is not necessarily limited to instances in which a personal relationship may exist, such as a mentorship or a scientific collaboration, or in cases where the scientific information may be in conflict with the editor's own scientific reporting/data. In considering whether a basis for recusal exists, an editor shall be guided by the need to avoid the appearance of conflict.
- 5) For submitted papers where an editor is a co-author, the manuscript will be handled by a member of the Society of Biological Psychiatry (SOBP) Editorial Committee who does not have a conflict of interest with respect to that editor/author or the other authors of the paper. Editorially-focused content (e.g., commentaries, editorials) is exempt from this rule; in

such cases, an editor may handle a paper when a different editor is a co-author as long as no other potential conflicts exist between them (e.g., same affiliation).

- 6) Interests or relationships belonging to an immediate family member of an editor constitute a major conflict of interest for said editor to the same extent that it would if such interest or relationship belonged to said editor directly. Any editor having such a family-related major conflict of interest shall recuse him/herself from the editorial process relating to all manuscripts where such conflict exists.
- 7) An editor shall not use any confidential information obtained from his/her editorial activities with the journals to further his/her own or others' financial interests or personal or professional gain.

Reported Relationships for *Biological Psychiatry*, by Editor

Editor	Financial Relationships	
	Minor Conflicts or \leq \$10,000	Major Conflicts or $>$ \$10,000
Anissa Abi-Dargham <i>Deputy Editor</i>	Boehringer Ingelheim International - <i>Scientific Advisory Board</i> Herophilus - <i>Scientific Advisory Board</i> - <i>Stockholder</i> Merck - <i>DSMB</i> Neurocrine - <i>Scientific Advisory Board</i> <i>Neuropsychopharmacology</i> (ACNP) - <i>Deputy Editor</i> Roche - <i>Consultant</i> Sunovion - <i>Scientific Advisory Board</i> - <i>Consultant</i> Terran Life Sciences - <i>Scientific Advisory Board</i> - <i>Stock options</i>	Stony Brook University - <i>Employed</i>
Deanna M. Barch <i>Deputy Editor</i>	ACNP - <i>Council</i> Bipolar Roadmap Initiative Scientific Advisory Committee - <i>Scientific Advisory Board</i> Brain & Behavior Research Foundation - <i>Scientific Board</i> Flux Society for Developmental Cognitive Neuroscience - <i>Treasurer</i> One Mind - <i>Scientific Board</i> Stanley Center - <i>Advisory Board</i> Wellcome Trust - <i>Interview Panel</i>	Washington University - <i>Employed</i>

Edward T. Bullmore <i>Deputy Editor</i>	Academic Press, Elsevier -Book royalties Academy of Medical Sciences -Hon Treasurer and Council member Boehringer Ingelheim -Scientific Advisory Board Brain & Behavior Research Foundation -Scientific Council Brain Resource Company -Scientific Advisory Board -Stockholder Monument Therapeutics -Scientific Advisory Board Sosei Heptares -Scientific Advisory Board	Cambridgeshire & Peterborough NHS Foundation Trust -Non-executive director GlaxoSmithKline -Consultant -Research funding Janssen -Research funding Lundbeck -Research funding Short Books, Picador -Book Royalties University of Cambridge -Employed
Cameron S. Carter <i>Deputy Editor</i>	Brain & Behavior Research Foundation -Scientific Council NIH Center for Scientific Review -Ad hoc reviewer One Mind -Scientific Board	University of California, Davis -Employed
Daniel Geschwind <i>Deputy Editor</i>	AcuraStem -Advisory Board Allen Institute -Scientific Advisory Board Axial Biotherapeutics, Inc. -Scientific Advisory Board Elsevier -Book Royalties	Larry L. Hillblom Foundation -Scientific Advisory Board University of California, Los Angeles -Employed Patent: -Compositions and Methods for Treating Tauopathies; US Provisional Application # 63/151,448. Filed February 19, 2021
Tamar L. Gur <i>Social Media Editor</i>		Ohio State -Employed
Paul J. Harrison <i>Deputy Editor</i>	Oxford University Press -Book royalties Research England -Panel honorarium	University of Oxford -Employed
John H. Krystal <i>Editor</i>	Aptinyx, Inc. -Consultant AstraZeneca Pharmaceuticals -Consultant -Research study drug (Saracatinib) Biogen Inc. -Consultant Bionomics Limited (Australia) -Consultant BioXcel Therapeutics, Inc. -Clinical Advisory Board Boehringer Ingelheim International -Consultant Cerevel Therapeutics, LLC -Research Study Drug PF-06412562 -Scientific Advisory Board Clearmind Medicine, Inc. -Consultant -Stock options Cybin IRL (Ireland Limited Company)	Biohaven Pharmaceuticals Medical Sciences -Scientific Advisory Board -Stockholder -Stock options Freedom Bioscience, Inc. -Science Advisory Board Janssen Research & Development -Consultant Patents: -Seibyl JP, Krystal JH, Charney DS. Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizoph- renia; US Patent # 5,447,948. Issued Sept 5, 1995 -Coric V, Krystal JH, Sanacora G. Glutamate Modulating Agents in the Treatment of Mental Disorders; US Patent # 8,778,979. B2 Issued July 15, 2014; US Patent Application No. 15/695,164: Filed Sept 5, 2017

	<p>-<i>Consultant</i> Delix Therapeutics, Inc. - <i>Scientific Advisory Board</i> Eisai, Inc. -<i>Scientific Advisory Board</i> Epiodyne, Inc. -<i>Consultant</i> Enveric Biosciences -<i>Consultant</i> EpiVario, Inc. -<i>Consultant</i> -<i>Scientific Advisory Board</i> -<i>Stock options</i> Jazz Pharmaceuticals Inc. -<i>Consultant</i> -<i>Scientific Advisory Board</i> Neumora Therapeutics -<i>Scientific Advisory Board</i> -<i>Stock options</i> Neurocrine Biosciences, Inc. -<i>Scientific Advisory Board</i> Novartis Pharmaceuticals Corporation -<i>Research study drug (mavoglurant)</i> -<i>Scientific Advisory Board</i> Otsuka Pharmaceuticals -<i>Consultant</i> Perception Neuroscience, Inc. -<i>Consultant</i> -<i>Scientific Advisory Board</i> Praxis Precision Medicines, Inc. -<i>Consultant</i> -<i>Scientific Advisory Board</i> PsychoGenics, Inc. -<i>Scientific Advisory Board</i> Spring Care, Inc. -<i>Consultant</i> -<i>Stock</i> Sunovion Pharmaceuticals, Inc. -<i>Consultant</i> Takeda Industries - <i>Scientific Advisory Board</i> Tempero Bio, Inc. -<i>Scientific Advisory Board</i> -<i>Stock options</i> Terran Life Sciences -<i>Scientific Advisory Board</i> -<i>Stock options</i></p>	<p>-Charney DS, Krystal JH, Manji H, Mathew S, Zarate C. Intranasal Administration of Ketamine to Treat Depression; US Patent #9592207; Issued Mar 14, 2017; Licensed to Janssen Research & Development -Zarate C, Charney DS, Manji HK, Mathew SJ, Krystal JH, Yale University. Methods for Treating Suicidal Ideation; Patent Application # 15/379,013. Filed Dec 14, 2016, by Yale University Office of Cooperative Research -Arias A, Petrakis I, Krystal JH. Composition and Methods to Treat Addiction; Provisional Use Patent Application # 61/973/961. Filed April 2, 2014 by Yale University Office of Cooperative Research -Chekroud A, Gueorguieva R, Krystal JH. Treatment Selection for Major Depressive Disorder; USPTO docket # Y0087.70116US00. Provisional Patent Filed June 3, 2016 by Yale University -Gihyun Y, Petrakis I, Krystal JH. Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases; US Provisional Patent Application #62/444,552. Filed Jan 10, 2017 by Yale University Office of Cooperative Research #7088 US01 -Abdallah C, Krystal JH, Duman R, Sanacora G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. US Provisional Patent Application #62/719,935. Filed Aug 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01 -Krystal JH, Pearlson G, O'Malley S, Potenza M, Gasparini F, Gomez-Mancilla B, Malaterre V. Mavoglurant in treating gambling and gaming disorder. US Provisional Patent Application #63/125,181. Filed Dec 14, 2020 by Yale University Office of Cooperative Research VA Connecticut Healthcare System -<i>Employed</i> Yale University School of Medicine -<i>Employed</i></p>
Ellen Leibenluft <i>Reviews Editor</i>		National Institutes of Health - <i>Employed</i>
Eric J. Nestler <i>Deputy Editor</i>	EpiVario - <i>Scientific Advisory Board</i>	Berg Pharma - <i>Board of Directors</i>

	Intra-Cellular Therapies, Inc. <i>-Scientific Advisory Board</i>	Icahn School of Medicine at Mount Sinai <i>-Employed</i> PsychoGenics <i>-Founder and Chair</i> <i>-Scientific Advisory Board</i> Rainwater Foundation <i>-Scientific Advisory Board Chair</i>
David A. Ross <i>Education Editor</i>	Scutmonkey Consulting, LLC <i>-Co-founder</i>	Alberta Health Services <i>-Employed</i> University of Alberta Faculty of Medicine and Dentistry <i>-Employed</i> VA Connecticut Healthcare System <i>-Previously employed (ended Jan 2022)</i> Yale University School of Medicine <i>-Previously employed (ended Jan 2022)</i>
Murray B. Stein <i>Deputy Editor</i>	Acadia Pharmaceuticals <i>-Consultant</i> Aptinyx <i>-Consultant</i> Atai Life Sciences <i>-Consultant</i> Bionomics <i>-Consultant</i> BioXcel Therapeutics <i>-Consultant</i> Boehringer Ingelheim <i>-Consultant</i> Brain & Behavior Research Foundation <i>-Scientific Board</i> Clexio <i>-Consultant</i> Engrail Therapeutics <i>-Consultant</i> Epivario <i>-Consultant</i> <i>-Stock options</i> Janssen Research and Development <i>-Consultant</i> Jazz Pharmaceuticals <i>-Consultant</i> Neurotrauma Sciences <i>-Consultant</i> Oxeia Biopharmaceuticals <i>-Consultant</i> <i>-Stock options</i> Roche/Genentech <i>-Consultant</i> Sumitomo Pharma <i>-Consultant</i>	<i>Depression and Anxiety</i> <i>-Editor-in-Chief</i> EmpowerPharm <i>-Consultant</i> University of California, San Diego <i>-Employed</i> <i>UpToDate</i> <i>-Co-Editor-in-Chief for Psychiatry</i> VA San Diego Healthcare System <i>-Employed</i>